Important Risk Information
Do not compress HEMOPATCH into blood vessels or use intravascularly.
The device must not be used in patients with known hypersensitivity to bovine proteins or brilliant blue.
HEMOPATCH is not intended to be used in pulsatile, severe bleedings.
The use of HEMOPATCH is not recommended in the presence of an active infection.
When used in, around, or in proximity to foramina in bone, areas of bony confine, the spinal cord, the brain and/or cranial nerves, care should be exercised to avoid overpacking, creating the potential for neural damage.
HEMOPATCH is not intended as a substitute for meticulous surgical technique and the proper application of ligatures or other conventional procedures for hemostasis and sealing.
About Baxter
Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
This release includes forward-looking statements concerning HEMOPATCH, including expectations with regard to its availability in the European Union and risks associated with its use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.
Contacts
Baxter International Inc.
Media Contact
Bill Rader, (224) 948-5353
media@baxter.com
or
Investor Contact
Clare Trachtman, (224) 948-3085
Back to HCB News